Choosing Between Antithrombotic Strategies for Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Bivalirudin does not reduce major cardiovascular events compared with heparin with or without glycoprotein IIb/IIIa inhibitors.

To gain insight into the comparative benefits of bivalirudin and heparin with or without additional glycoprotein IIb/IIIa inhibitors, researchers conducted MATRIX Antithrombin, a randomized, controlled trial involving 7213 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention; 4010 patients had ST-segment elevation (STEACS), and 3203 did not (NSTEACS).

In the STEACS group, bivalirudin and heparin produced no statistical difference in the coprimary endpoint, major adverse cardiovascular events (MACEs; a composite of death, myocardial infarction, and stroke) at 30 days (5.9% and 6.5%). No relevant between-group difference was found in the other coprimary endpoint, net adverse clinical events (a composite of…

Reviewing Author

Pascal Meier, MD

Disclosures

Editorial BoardsOpen Heart

Leadership Positions in Professional SocietiesEuropean Society of Cardiology (Communication Committee); European Association of Percutaneous Cardiovascular Interventions (Chair, Web & Communication Committee)

Pascal Meier, MD

Disclosures

Editorial BoardsOpen Heart

Choosing Between Antithrombotic Strategies for Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Topics

Reviewing Author